

Enosium Life Science Accelerates Path to European Leadership in Healthcare Scientific Services with Three Strategic Acquisitions

- **Inbeeo:** A leading consulting firm specializing in market access and pricing strategies for pharmaceutical drugs and medical devices in Europe.
- **Vyoo Agency:** One of the few highly specialized companies in health economics and outcomes research (HEOR).
- **Epione:** A major historical player in the French market for medical and scientific communication, known for its brands KPL, ALINEA PLUS, and SIRIUS.

Paris, October 03, 2024 – Enosium Life Science, a group specialized in life sciences, accelerates its growth with three strategic acquisitions in France and the United Kingdom. By integrating Inbeeo, Vyoo Agency and Epione, Enosium Life Science distinguishes itself in Europe with a unique offering of tailored and innovative solutions, addressing the needs of the pharmaceutical, biotechnology, and Medtech industries.

Inbeeo and **Vyoo Agency** support pharmaceutical and medtech companies with personalized strategies and solutions, facilitating market access and the value optimization of innovative drugs in a particularly complex environment regarding pricing, access conditions and commercialization in Europe.

The French group **Epione** and its three entities—KPL, the French specialist in medical affairs; Alinéa Plus, the entity dedicated to scientific events and conferences; and Sirius Customizer, specializing in strategic consulting and patient’s journey—bring their expertise and know-how in medical communication to meet the needs of healthcare stakeholders with scientific rigor and creativity.

These acquisitions mark a major milestone in Enosium Life Science’s growth, with consolidated revenues nearing €15 million and a team of 70 employees. Specifically, this reinforces the group's ambition to build a multi-specialist organization covering the entire value chain of healthcare products, from clinical development to commercialization.

Enosium Life Science plans to continue its external growth strategy in the coming months while focusing on integrating and developing synergies between its various entities. These synergies will help create a unique, high-value consulting offering to support clients in successfully launching their innovations across Europe.

Antoine Amer, founder and CEO of Enosium Life Science, commented: *“I am very thrilled and proud to welcome Hervé Lilliu, Founder of Inbeeo, Stéphane Roze, Founder of Vyoo Agency, Catherine Auzimour, and Pierre-Louis Prost, co-founders of the Epione group, along with their 65 talented and internationally renowned experts. Our goal is to rapidly establish ourselves as the partner of choice for pharmaceutical, biotech, and Medtech companies by providing highly specialized scientific consulting across all European markets and throughout the entire healthcare product value chain. We are committed to becoming a European leader in the sector by continuing our external growth strategy in the coming months while fostering synergies across our various entities. Our mission is to help our clients successfully launch*

their innovations in France and Europe, ensuring faster and broader access for European patients to high-quality medical breakthroughs."

Hervé Lilliu, President and Founder of Inbeeo, said: *"We are very pleased to join Enosium Life Science, with whom we share a common vision: accelerating access to innovation for everyone. Becoming part of this new, integrated group—unique in Europe—enables us to deliver cutting-edge scientific services and strategic consulting to the healthcare industry."*

Stéphane Roze, President and Founder of Vyoo Agency, declared: *"Joining a group like Enosium Life Science will allow us to access larger markets and create valuable synergies with other specialized expertise that our clients both need and actively seek."*

Catherine Auzimour and Pierre-Louis Prost, founding partners of the Epione group (KPL, SIRIUS-CUSTOMIZER, ALINEA PLUS), stated: *"We are excited to join Enosium and contribute to the creation of a new group with robust expertise across the entire pharmaceutical value chain, with whom we share a commitment to personalized services, expert guidance, and client satisfaction. The synergies we create will enhance the offerings of the Epione group (KPL, SIRIUS-CUSTOMIZER, ALINEA PLUS), enabling us to better address the challenges faced by pharmaceutical companies and position ourselves as a leading European player in medical affairs."*

Basile Paul-Petit, Partner at Otium, added: *"We have a strong belief in Enosium's value potential and its strategy of integrating excellent scientific services of the European healthcare ecosystem. These acquisitions are a testament to that, positioning Enosium as a leading player in the sector, ready to redefine healthcare services with innovative solutions."*

For more information, watch the video interview with Dr. Antoine Amer: [LINK](#)

About Enosium Life Science

Founded in January 2024 by Dr. Antoine Amer with financial support from Otium, Enosium Life Science is an integrated group offering scientific services (clinical research, regulatory affairs, market access and medico-economic value optimization, medical affairs, and marketing) to the healthcare industry across Europe. Its mission is to unite the best expertise from across Europe to provide a unique and comprehensive range of scientific services, supporting innovation and excellence in life sciences, and ultimately enabling faster and broader access for European patients to medical innovations. The group has nearly 70 employees and generates a revenue of €15 million.

For more information: www.enosium.com.

About Otium

Otium is a long-term investment holding company founded in 2009 by Pierre Edouard Sterin. With €1.5 billion in assets under management as of April 30, 2024, spread across more than 100 investments – including the Smartbox group and stakes in French unicorns PayFit and Owkin – Otium invests amounts ranging from a few hundred thousand euros to several tens of millions of euros. Companies are funded at every stage of their development, from seed funding to growth capital, and Otium takes either majority or minority stakes with no holding



period constraints. Otium pursues a diversification strategy by financing projects in tech, industrials, leisure, healthcare, hospitality and real estate. Otium invested €190 million in 2023.

As a community-engaged actor, Otium contributes to supporting the Fonds du Bien Commun, a philanthropic organization that partners with social and associative entrepreneurs working to build tomorrow's society.

Contact Enosium Life Science

FP2COM

Florence Portejoie

06 07 76 82 83, fportejoie@fp2com.fr

Contact Otium

Image Sept

otium@image7.fr